Cullinan Oncology rises as FDA clears blood cancer therapy for clinical trials

Cullinan Therapeutics

01/03/2024 15:53

** Shares of drug developer Cullinan Oncology  CGEM.O  rise
2.1% to $18.85 in morning trade
    ** Company says the U.S. FDA has given it clearance to start
trials on its experimental cancer therapy for multiple myeloma
    ** Multiple myeloma is a form of blood cancer that affects a
type of white blood cells called plasma cells, found in bone
marrow
    ** The therapy, CLN-619, has already been cleared for
clinical trials in solid tumors
    ** Stock up 67% in the last 12 months

 (Reporting by Puyaan Singh)
 ((Puyaan.Singh@thomsonreuters.com;))